7 completed, 7 recruiting, 4 unknown, 2 terminated. 24 Phase 1, 11 Phase 2.
Follow Relapse: new trials by email Literature Review of Relapse trials Research Report on Relapse
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Safety and Efficacy of Daratumumab in Patients With Refractory Aplastic Anemia Daratumumab - Aplastic Anemia, Refractory | Phase 1 / Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 37 | 2025-12-17 | 2026-11-06 |
| CD7 CAR T Cells (RD13-02) in the Treatment of Relapsed/Refractory Severe Aplastic Anemia RD13-02 - Severe Aplastic Anemia, Relapse | Phase 1 | Suspended | Institute of Hematology & Blood Diseases Hospital, China | 15 | 2025-06-19 | 2026-11-04 |
| Chiglitazar Sodium Combined With Venetoclax and Azacitidine (CVA) for the Treatment of R/R AML CVA - Acute Myeloid Leukemia, Relapse | Phase 1 | Recruiting | The First Affiliated Hospital of Xiamen University | 30 | 2025-03-15 | 2025-02-24 |
| Autologous CAR-T Cells Targeting B7-H3 in PDAC iC9-CAR.B7-H3 T cell infusion - Pancreas Cancer, Relapse | Phase 1 | Recruiting | UNC Lineberger Comprehensive Cancer Center | 27 | 2024-07-18 | 2026-06-08 |
| Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells iC9-CAR.B7-H3 T Cell Therapy, cyclophosphamide, fludarabine - Breast Cancer, Relapse | Phase 1 | Recruiting | UNC Lineberger Comprehensive Cancer Center | 42 | 2024-06-27 | 2026-07-28 |
| ATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 Cells Chemotherapy, Cell infusion - Hodgkin Lymphoma, Relapse | Phase 1 / Phase 2 | Recruiting | UNC Lineberger Comprehensive Cancer Center | 31 | 2024-04-25 | 2026-08-06 |
| Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCC Cyclophosphamide, Fludarabine, Cell Therapy - Head and Neck Cancer, Relapse | Phase 1 | Recruiting | UNC Lineberger Comprehensive Cancer Center | 33 | 2024-04-05 | 2026-11-05 |
| Allogeneic Immunotherapy of Hematological Malignancies Using Regulatory T-cell Selective Depletion T-reg depleted DLI - Hematological Malignancies, Regulatory T Cell Depletion | Phase 1 / Phase 2 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 27 | 2024-03-01 | 2024-02-14 |
| A Phase 1 Clinical Trial of AUR106 in Patients With Relapsed Advanced Malignancies AUR106 - Relapse, Advanced Malignant Neoplasm | Phase 1 | Terminated | Aurigene Discovery Technologies Limited | 21 | 2023-08-26 | 2026-04-17 |
| Dual Target CAR-T Cells in B-cell Acute Lymphoblastic Leukemia Dual target CAR-T cell therapy - Dual-target CAR-T Cells, B ALL | Phase 1 / Phase 2 | Unknown | Shenzhen University General Hospital | 20 | 2020-10-20 | 2021-01-26 |
| Dose-Escalation Study of Oral Administration of LP-108 as Monotherapy and in Combination With Azacitidine in Patients With Relapsed or Refractory MDS, CMML, or AML LP-108, LP-108 and azacitidine - AML/MDS, CMML | Phase 1 | Completed | Newave Pharmaceutical Inc | 32 | 2020-07-06 | 2026-01-23 |
| Epacadostat, Cladribine and Cytarabine (ECC) in AML Epacadostat, Cladribine, Cytarabine - AML, Relapse | Phase 1 | Withdrawn | Insel Gruppe AG, University Hospital Bern | 2018-12-01 | 2018-09-11 | |
| IA Carboplatin + Radiotherapy in Relapsing GBM IA Carbo+ Radiation - Glioblastoma Multiforme, Relapse | Phase 1 / Phase 2 | Recruiting | Université de Sherbrooke | 35 | 2018-07-10 | 2025-08-11 |
| CD19 CAR-T Cells With CRS Suppression Technology for r/r CD19+ Acute Lymphoblastic Leukemia CD19 CAR-T cells, CD19 CAR-T cells with CRS suppression technology - Acute Lymphoblastic Leukemia, CD19 Positive | Phase 1 / Phase 2 | Unknown | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd | 40 | 2017-07-01 | 2024-05-28 |
| CD19 CAR T Cells in Patients With Relapsed or Refractory CD19 Positive B-cell Lymphoma CD19 CAR T cells - Lymphomas Non-Hodgkin's B-Cell, Relapse | Phase 1 | Completed | Institute of Hematology & Blood Diseases Hospital, China | 20 | 2017-06-08 | 2026-02-11 |
| Chidamide Plus DCAG for Relapsed/Refractory AML Chidamide plus DCAG regimen - AML, Relapse | Phase 1 / Phase 2 | Unknown | Chinese PLA General Hospital | 100 | 2016-06-01 | 2018-02-14 |
| Ketamine for Relapse Prevention in Recurrent Depressive Disorder Ketamine, Midazolam - Depression, Relapse | Phase 1 | Terminated | St Patrick's Hospital, Ireland | 9 | 2015-12-01 | 2020-01-13 |
| Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies Carfilzomib, Tacrolimus - Hematologic Malignancies, Relapse | Phase 1 / Phase 2 | Completed | University of Michigan Rogel Cancer Center | 53 | 2014-10-01 | 2022-01-03 |
| Phase I/II Feasibility Study Combining Brentuximab Vedotin With Second Line Salvage Chemotherapy (DHAP) in Hodgkin Lymphoma Patients DHAP, Brentuximab Vedotin, Autologous Peripheral Blood Stem Cell Transplantation - Hodgkin Lymphoma, Refractory | Phase 1 | Unknown | Marjolein Spiering | 72 | 2014-05-01 | 2018-03-13 |
| TPI 287 in Patients With Refractory or Recurrent Neuroblastoma or Medulloblastoma TPI 287 - Neuroblastoma, Medulloblastoma | Phase 1 | Completed | Giselle Sholler | 18 | 2009-03-01 | 2024-08-06 |
Showing 20 of 24. Sign in to see all of them.
Recurrence (24) · Hematologic Neoplasms (3) · Hodgkin Disease (3) · Lymphoma (3) · Multiple Myeloma (3) · Anemia, Aplastic (2) · Leukemia, Myeloid, Acute (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Breast Neoplasms (1) · Burkitt Lymphoma (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Transitional Cell (1) · Colonic Neoplasms (1) · Depression (1) · Depressive Disorder (1)
Disease Attributes (24) · Pathologic Processes (24) · Pathological Conditions, Signs and Symptoms (24) · Neoplasms (18) · Hemic and Lymphatic Diseases (15) · Neoplasms by Histologic Type (14) · Hematologic Diseases (10) · Immune System Diseases (10) · Immunoproliferative Disorders (10) · Lymphoproliferative Disorders (10) · Lymphatic Diseases (8) · Neoplasms by Site (7) · Blood Protein Disorders (3) · Cardiovascular Diseases (3) · Hemorrhagic Disorders (3)
Cell- and Tissue-Based Therapy (2) · Cyclophosphamide (2) · fludarabine (2) · fludarabine phosphate (2) · Azacitidine (1) · Bortezomib (1) · Brentuximab Vedotin (1) · Cisplatin (1) · Cladribine (1) · Cytarabine (1) · Dexamethasone (1) · Drug Therapy (1) · Insulin Infusion Systems (1) · Ketamine (1) · Lenalidomide (1)
UNC Lineberger Comprehensive Cancer Center (4) · Institute of Hematology & Blood Diseases Hospital, China (3) · Assistance Publique - Hôpitaux de Paris (2) · Aurigene Discovery Technologies Limited (1) · Baylor College of Medicine (1) · Chinese PLA General Hospital (1) · Giselle Sholler (1) · Insel Gruppe AG, University Hospital Bern (1) · Janssen Pharmaceutical K.K. (1) · Marjolein Spiering (1) · Newave Pharmaceutical Inc (1) · Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd (1) · Shenzhen University General Hospital (1) · St Patrick's Hospital, Ireland (1) · The First Affiliated Hospital of Xiamen University (1)
United States (8) · China (7) · France (2) · Canada (1) · Denmark (1) · Germany (1) · India (1) · Ireland (1) · Netherlands (1) · Spain (1) · Switzerland (1) · United Kingdom (1)
Akhil Kumar, MD (1) · Anton Hagenbeek, PhD MD (1) · Ashwin Somasundaram, MD (1) · Attaphol Pawarode, M.D. (1) · Bing Xu (1) · David Fortin, MD (1) · Declan McLoughlin (1) · Dehui Zou, Dr. (1) · Giselle Sholler, MD (1) · Helen E Heslop, MD (1) · Jared Weiss, MD (1) · Li Yu, Dr (1) · Li Yu, MD. Ph.D (1) · Li-Xin Wang, MD. Ph.D. (1)
PMID 19182205, PMID 19534336, PMID 19760366, PMID 20650872, PMID 22284691, PMID 22931705, PMID 23844725, PMID 24026531, PMID 24947313, PMID 29315015, PMID 32273476, PMID 32873343, PMID 33235353, PMID 36105799, PMID 36241696, PMID 37722357, PMID 40960310
2015 (1), P50CA058223 (1), R01CA296807 (1)